Live Analyst Rating Changes 1526 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Wiederhorn
OPCO
Michael Wiederhorn
Oppenheimer
Wall Street Analyst
★★★☆☆
#1064
on 13Foresight · ranked by our own returns
65%
Success Rate
+7.5%
Average Return
13 of 20 calls profitable · -3300.2% vs benchmark
📈 Across the calls we could measure, roughly 65% of Michael Wiederhorn's ratings turned a profit when each position was held for 1 year — averaging +7.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

63 Buy 5 Hold 0 Sell
Michael's Stock Coverage 20 ratings · 2026-06-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
PACS
PACS Group Inc
 May 13, 2026 BUY Strong Buy
+19.4% avg upside
9 analysts
$48.00
31.13% Upside
 -14.7%
PNTG
Pennant Group
 May 08, 2026 BUY Strong Buy
+5.8% avg upside
9 analysts
$40.00
19.70% Upside
 -3.7%
GRDN
Guardian Pharmacy Services, Inc. Class A
 May 07, 2026 BUY Strong Buy
-1.0% avg upside
7 analysts
$43.00
1.45% Upside
 +6.1%
ADUS
Addus Homecare
 May 06, 2026 BUY Strong Buy
+35.9% avg upside
18 analysts
$155.00
64.55% Upside
 -3.3%
HUM
Humana
 Apr 30, 2026 BUY Buy
-11.2% avg upside
34 analysts
$260.00
27.93% Downside
 +53.1%
CNC
Centene
 Apr 29, 2026 BUY Buy
+8.6% avg upside
28 analysts
$58.00
4.96% Downside
 +12.3%
HCA
HCA Healthcare
 Apr 27, 2026 BUY Buy
+14.7% avg upside
35 analysts
$520.00
38.58% Upside
 -12.8%
CYH
Community Health
 Apr 23, 2026 BUY Sell
+44.8% avg upside
18 analysts
$4.00
32.52% Upside
 +13.2%
UNH
UnitedHealth
 Apr 22, 2026 BUY Strong Buy
+2.3% avg upside
35 analysts
$405.00
0.99% Upside
 +14.1%
CHE
Chemed
 Mar 31, 2026 BUY Buy
+9.6% avg upside
5 analysts
$500.00
14.63% Upside
 +11.2%
EVH
Evolent Health
 Mar 20, 2026 BUY Strong Buy
+123.4% avg upside
19 analysts
 — +63.6%
ENSG
The Ensign Group
 Mar 20, 2026 BUY Strong Buy
+5.3% avg upside
9 analysts
 — -23.2%
TDOC
Teladoc
 Mar 03, 2026 BUY Buy
+256.9% avg upside
37 analysts
$7.00
13.30% Downside
 +39.0%
CCRN
Cross Country Healthcare
 Nov 19, 2025 HOLD Hold
+20.0% avg upside
15 analysts
 — +13.4%
CI
Cigna
 Oct 31, 2025 BUY Strong Buy
+24.2% avg upside
29 analysts
$365.00
30.67% Upside
 +18.6%
CVS
CVS Health
 Aug 09, 2024 HOLD Strong Buy
+3.2% avg upside
38 analysts
 — +20.0%
UPHL
UpHealth
 Mar 02, 2023 BUY Strong Buy
+2683233.4% avg upside
6 analysts
$3.00
999900.05% Upside
 -68.4%
CG
Carlyle Group
 Feb 09, 2018 BUY Buy
+25.5% avg upside
25 analysts
$35.00
21.80% Downside
 -13.4%
ELV
Elevance Health
 Jun 07, 2017 HOLD Strong Buy
+10.9% avg upside
32 analysts
 — +23.5%
GENNQ
Genesis Healthcare
 Aug 19, 2014 BUY Buy
+53914710.0% avg upside
5 analysts
$7.00
6999899.93% Upside
 ·
🔒 15 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Michael Wiederhorn — Frequently Asked Questions
How accurate are Michael Wiederhorn's stock ratings?
Based on the calls 13Foresight could measure, about 65% of Michael's ratings were profitable over a one-year hold, with an average return of +7.5% per rating, or -3300.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Michael ranked on 13Foresight?
Michael Wiederhorn is currently ranked #1064 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on PACS, PNTG, GRDN, ADUS, HUM, CNC, HCA, CYH, UNH, CHE, EVH, ENSG and 8 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.